After striking out with previous administrations, petitioners backed by Knowledge Ecology International are once again asking the Department of Health and Human Services to grant march-in rights to Xtandi patents given the high price of the prostate cancer drug in the US. This is the first march-in case to come before the Biden Administration, which will test whether it supports using this mechanism to address drug pricing.
At a 15 December press briefing, KEI Director James Love said petitioners have asked HHS to conduct an administrative hearing...